What to Do When First-Line Antiseizure Therapy Has Not Controlled Myoclonic-Atonic Seizures
In epilepsy with myoclonic-atonic seizures, first-line antiseizure therapy does not always achieve adequate seizure control. When initial treatment falls short of the defined response targets, a structured second-line protocol is indicated.
Previous therapy — failure condition
First-line antiseizure medication — valproate (the primary recommended agent), clobazam, or clonazepam — did not achieve the required targets: a greater than 50% reduction in seizure frequency, or seizure freedom.
Treatment Targets
The goals of this protocol are a greater than 50% reduction in seizure frequency, with seizure freedom as the optimal outcome.
Second-Line Approach (partial overview)
This protocol describes a second-line strategy that includes a specific antiseizure agent strongly recommended for this seizure type, as well as a dietary intervention identified as an optimal second-line option. The complete selection criteria, sequencing, and full range of options are available in the structured regimen.
References
- Clonazepam was also considered a first-line option, whereas ethosuximide was strongly recommended as second-line therapy.
- A combination of valproate and ethosuximide might be effective, even if either drug fails individually.
- An international Delphi consensus endorsed valproate and clobazam as first-line treatments, with the ketogenic diet identified as the optimal second-line treatment.
- Studies reported seizure freedom with the ketogenic diet in 18–58% of patients with epilepsy with myoclonic-atonic seizures and a greater than 50% seizure reduction in 35–55%.
View source ↗